1. Medtech Insight
  2. >>Policy & Regulation

FCA: 2020 Sees More False Claims Cases Than Ever While Recoveries Plummet

 
• By Elizabeth Orr

A report from the law firm Gibson Dunn found that the US government brought more new cases under the False Claims Act last year than ever before, which they partially attribute to COVID-19 enforcement actions.

Washington DC, USA-June 5, 2018: Robert F Kennedy Department of Justice building entrance "The Place of Justice is a Hallowed Place" engraved in stone above the door

The coronavirus pandemic slowed down a lot of things in 2020, but efforts to root out the submission of fraudulent claims to government programs weren’t among them. The count of new cases that the US government and individual whistleblowers brought under the False Claims Act reached 922, making it the most active year on record, a report from the law firm Gibson Dunn says.

And the firm expects the surge to continue into 2021 and beyond. “Last year, the government enacted legislative stimulus packages totaling nearly $4tn in COVID-relief funds, and any time the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.